Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 108 | NANETS2024 | Next issue

NANETS 2024

17th Annual Multidisciplinary NET Medical Symposium NANETS 2024

Clinical - Chemo/SSA/Biologics

Previous section
Applied Basic Science
Table of contents
Next section
Clinical - Nuclear Medicine/Interventional Radiology/Imaging

ea0108c1 | Clinical - Chemo/SSA/Biologics

NP-101 in combination with nivolumab and ipilimumab in metastatic extra-pulmonary neuroendocrine carcinomas (EP-NECs): a pilot study

ea0108c2 | Clinical - Chemo/SSA/Biologics

Preliminary clinical activity of surufatinib combined with octreotide LAR in patients with G1/2 gastroenteropancreatic neuroendocrine tumor (GEP-NET)

ea0108c3 | Clinical - Chemo/SSA/Biologics

Prolonged response to dabrafenib/trametinib in metastatic well-differentiated grade 3 pancreatic neuroendocrine tumor (NET G3) with BRAF V600E mutation

ea0108c4 | Clinical - Chemo/SSA/Biologics

Comparison of survival outcomes and hypoglycemic control in patients receiving systemic therapy for malignant insulinoma

ea0108c5 | Clinical - Chemo/SSA/Biologics

Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study

ea0108c6 | Clinical - Chemo/SSA/Biologics

Evaluation of switching SSAs on GI-NET progression – experience at an academic medical center

ea0108c7 | Clinical - Chemo/SSA/Biologics

Cabozantinib therapy in patients with previously treated well differentiated grade 3 neuroendocrine tumors (G3 NETs)

ea0108c8 | Clinical - Chemo/SSA/Biologics

Temozolomide induced hypermutation in pancreatic neuroendocrine tumors: a case series

ea0108c9 | Clinical - Chemo/SSA/Biologics

Updated results of CABINET trial/alliance A021602: cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy

ea0108c10 | Clinical - Chemo/SSA/Biologics

RZ358 (ersodetug) as a novel therapy for hypoglycemia due to tumor hyperinsulinism: outcomes from an expanded access program for compassionate use

ea0108c11 | Clinical - Chemo/SSA/Biologics

Survivin and DLL-3 as predictors of survival in low-grade neuroendocrine tumor patients

ea0108c12 | Clinical - Chemo/SSA/Biologics

Updated phase 1 data for the DLL3/CD3 IgG-like T-cell engager BI 764532 in DLL3-positive tumors: focus on extrapulmonary neuroendocrine carcinomas

ea0108c13 | Clinical - Chemo/SSA/Biologics

Patterns of long-term remission or apparent cure in a cohort of patients with grade 3 neuroendocrine neoplasms (NENs)

ea0108c14 | Clinical - Chemo/SSA/Biologics

Approach integrating ERCP with radiofrequency ablation for long-term management for metastatic pancreatic NET to biliary tree as klatskin tumor

ea0108c15 | Clinical - Chemo/SSA/Biologics

RECIST for the real world: impact of response evaluation criteria in solid tumors compared to standard radiology reports on physician decisions and patient satisfaction

ea0108c16 | Clinical - Chemo/SSA/Biologics

Targeted alpha therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors

ea0108c17 | Clinical - Chemo/SSA/Biologics

ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: phase 1b safety/efficacy

ea0108c18 | Clinical - Chemo/SSA/Biologics

DNA damage repair mutational status’s effect on Lu-177-DOTATATE in combination with olaparib in metastatic SSTR+ GI neuroendocrine tumor: preliminary results

ea0108c19 | Clinical - Chemo/SSA/Biologics

Safety of lutetium-177 DOTATATE treatment in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more